Key facts
- It has raised $24.5M; the latest was IPO ($10.3M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Korea Development Bank, Korea Credit Guarantee Fund, Mirae Asset Capital — 23 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for RecensMedical (KRX: 394420)
- ·The full record, as it builds
Funding rounds
No funding rounds for RecensMedical (KRX: 394420) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RecensMedical (KRX: 394420)
RecensMedical Inc is a specialized medical device company that provides precision cryotherapy and transdermal drug delivery solutions based on its independently developed cryogenic-thermoelectric combined rapid precision cooling technology platform. Its products include: TargetCool; and VetEase. Recense Medical's Rapid Precision Cooling Technology enables safe and effective cooling procedures by precisely controlling cooling temperatures at ultra-high speeds using patented cryogenic pressure control technology.
- Sector
- Healthcare
- HQ
- Hwaseong-si, South Korea
- Founded
- 2016
- Employees
- 55
- Website
- recensmedical.co.kr/
- Ownership
- Publicly Held
RecensMedical (KRX: 394420) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RecensMedical (KRX: 394420) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RecensMedical (KRX: 394420) in its N-PORT filings yet. We sweep new filings monthly.